IL208980A - Antibody to granulocyte-macrophage factor stimulates colony - Google Patents
Antibody to granulocyte-macrophage factor stimulates colonyInfo
- Publication number
- IL208980A IL208980A IL208980A IL20898010A IL208980A IL 208980 A IL208980 A IL 208980A IL 208980 A IL208980 A IL 208980A IL 20898010 A IL20898010 A IL 20898010A IL 208980 A IL208980 A IL 208980A
- Authority
- IL
- Israel
- Prior art keywords
- granulocyte
- antibodies
- stimulating factor
- macrophage colony
- macrophage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4852208P | 2008-04-28 | 2008-04-28 | |
| PCT/US2009/041981 WO2009134805A2 (en) | 2008-04-28 | 2009-04-28 | Antibodies to granulocyte-macrophage colony-stimulating factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL208980A0 IL208980A0 (en) | 2011-01-31 |
| IL208980A true IL208980A (en) | 2015-06-30 |
Family
ID=41255734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL208980A IL208980A (en) | 2008-04-28 | 2010-10-28 | Antibody to granulocyte-macrophage factor stimulates colony |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8168183B2 (https=) |
| EP (2) | EP2280732B1 (https=) |
| JP (1) | JP5688363B2 (https=) |
| KR (2) | KR101824512B1 (https=) |
| CN (1) | CN102037016B (https=) |
| AU (1) | AU2009243184B2 (https=) |
| BR (1) | BRPI0911902A2 (https=) |
| CA (1) | CA2722137C (https=) |
| CO (1) | CO6311004A2 (https=) |
| DK (1) | DK2280732T3 (https=) |
| EA (1) | EA201001691A1 (https=) |
| ES (1) | ES2704835T3 (https=) |
| IL (1) | IL208980A (https=) |
| MX (1) | MX2010011761A (https=) |
| NZ (1) | NZ588850A (https=) |
| WO (1) | WO2009134805A2 (https=) |
| ZA (1) | ZA201008028B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE536374T1 (de) | 2006-09-01 | 2011-12-15 | Therapeutic Human Polyclonals Inc | Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| NZ588850A (en) | 2008-04-28 | 2012-12-21 | Kalobios Pharmaceuticals Inc | Antibodies to granulocyte-macrophage colony-stimulating factor |
| EP3056217B1 (en) * | 2008-12-22 | 2021-06-30 | The University of Melbourne | Osteoarthritis treatment |
| RU2630969C2 (ru) | 2008-12-22 | 2017-09-15 | Де Юниверсити Оф Мельбурн | Лечение боли |
| WO2012012571A1 (en) | 2010-07-21 | 2012-01-26 | Hans Zassenhaus | Biolayer interferometry measurement of biological targets |
| EP2729498A1 (en) | 2011-07-06 | 2014-05-14 | MorphoSys AG | Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof |
| US9400600B2 (en) * | 2011-12-16 | 2016-07-26 | Samsung Electronics Co., Ltd. | Method, apparatus, and graphical user interface for providing visual effects on a touchscreen display |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| EP2914289B1 (en) | 2012-10-31 | 2019-05-22 | Takeda GmbH | Lyophilized formulation comprising gm-csf neutralizing compound |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US10745475B2 (en) * | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| EP3139960B1 (en) | 2014-05-07 | 2024-01-17 | Takeda Pharmaceutical Company Limited | Liquid formulation comprising gm-csf neutralizing compound |
| CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
| EP3691663A4 (en) * | 2017-10-02 | 2021-08-18 | Humanigen, Inc. | METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| SG11202102317PA (en) * | 2018-09-10 | 2021-04-29 | Humanigen Inc | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
| SG11202103589XA (en) | 2018-10-31 | 2021-05-28 | Humanigen Inc | Materials and methods for treating cancer |
| TW202134278A (zh) | 2019-11-08 | 2021-09-16 | 美商胡曼尼根公司 | 用於治療腫瘤之ｅｐｈａ３導向ｃａｒ－ｔ細胞 |
| CN118561999B (zh) * | 2024-06-26 | 2025-03-14 | 武汉爱博泰克生物科技有限公司 | 抗人粒细胞-巨噬细胞集落刺激因子抗体、抗体对及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US7381801B2 (en) * | 2002-02-13 | 2008-06-03 | Ludwig Institute For Cancer Research | Chimerized GM-CSF antibodies |
| ES2263984T3 (es) * | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| JP4782700B2 (ja) | 2004-01-20 | 2011-09-28 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 最低限必須な結合決定基を用いた抗体特異性の移入 |
| US20060134098A1 (en) * | 2004-11-16 | 2006-06-22 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
| US7381802B2 (en) * | 2005-04-15 | 2008-06-03 | Universidad Nacional Autónoma De México (UNAM) | Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom |
| EP2468774A3 (en) * | 2005-04-18 | 2013-01-02 | Amgen Research (Munich) GmbH | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| EP3620171B1 (en) * | 2005-05-18 | 2022-04-20 | MorphoSys AG | Anti-gm-csf antibodies and uses therefor |
| US8211648B2 (en) | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
| KR20080068004A (ko) * | 2005-08-15 | 2008-07-22 | 아라나 테라퓨틱스 리미티드 | 뉴 월드 영장류 구조형성영역을 가진 조작 항체 |
| CA2641169C (en) * | 2006-02-08 | 2017-05-02 | Morphotek, Inc. | Antigenic gm-csf peptides and antibodies to gm-csf |
| US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| US20080206241A1 (en) | 2006-11-21 | 2008-08-28 | Kalobios Pharmaceuticals Inc. | Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| US8075885B2 (en) * | 2008-04-07 | 2011-12-13 | Kalobios Pharmaceuticals, Inc. | Methods of treating heart failure using an anti-GM-CSF antibody |
| NZ588850A (en) | 2008-04-28 | 2012-12-21 | Kalobios Pharmaceuticals Inc | Antibodies to granulocyte-macrophage colony-stimulating factor |
-
2009
- 2009-04-28 NZ NZ588850A patent/NZ588850A/xx not_active IP Right Cessation
- 2009-04-28 AU AU2009243184A patent/AU2009243184B2/en active Active
- 2009-04-28 WO PCT/US2009/041981 patent/WO2009134805A2/en not_active Ceased
- 2009-04-28 ES ES09739607T patent/ES2704835T3/es active Active
- 2009-04-28 EP EP09739607.1A patent/EP2280732B1/en active Active
- 2009-04-28 BR BRPI0911902A patent/BRPI0911902A2/pt not_active IP Right Cessation
- 2009-04-28 JP JP2011507586A patent/JP5688363B2/ja active Active
- 2009-04-28 KR KR1020107026423A patent/KR101824512B1/ko active Active
- 2009-04-28 MX MX2010011761A patent/MX2010011761A/es active IP Right Grant
- 2009-04-28 DK DK09739607.1T patent/DK2280732T3/en active
- 2009-04-28 EP EP18200356.6A patent/EP3449941A1/en not_active Ceased
- 2009-04-28 CN CN200980118423.0A patent/CN102037016B/zh active Active
- 2009-04-28 US US12/431,661 patent/US8168183B2/en active Active
- 2009-04-28 CA CA2722137A patent/CA2722137C/en active Active
- 2009-04-28 KR KR1020177023943A patent/KR101852915B1/ko active Active
- 2009-04-28 EA EA201001691A patent/EA201001691A1/ru unknown
-
2010
- 2010-10-28 IL IL208980A patent/IL208980A/en active IP Right Grant
- 2010-11-09 ZA ZA2010/08028A patent/ZA201008028B/en unknown
- 2010-11-25 CO CO10148019A patent/CO6311004A2/es not_active Application Discontinuation
-
2012
- 2012-04-30 US US13/460,151 patent/US9017674B2/en active Active
-
2015
- 2015-04-02 US US14/677,604 patent/US20150344565A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009243184B2 (en) | 2015-06-04 |
| US9017674B2 (en) | 2015-04-28 |
| US8168183B2 (en) | 2012-05-01 |
| WO2009134805A3 (en) | 2010-06-03 |
| JP2011518886A (ja) | 2011-06-30 |
| DK2280732T3 (en) | 2019-01-28 |
| EP3449941A1 (en) | 2019-03-06 |
| CN102037016B (zh) | 2015-06-03 |
| CA2722137C (en) | 2019-03-19 |
| KR20110011638A (ko) | 2011-02-08 |
| WO2009134805A2 (en) | 2009-11-05 |
| BRPI0911902A2 (pt) | 2015-10-13 |
| US20090274706A1 (en) | 2009-11-05 |
| KR101824512B1 (ko) | 2018-02-02 |
| MX2010011761A (es) | 2010-11-30 |
| IL208980A0 (en) | 2011-01-31 |
| ZA201008028B (en) | 2012-04-25 |
| EP2280732B1 (en) | 2018-10-17 |
| US20120213776A1 (en) | 2012-08-23 |
| ES2704835T3 (es) | 2019-03-20 |
| EA201001691A1 (ru) | 2011-10-31 |
| US20150344565A1 (en) | 2015-12-03 |
| CO6311004A2 (es) | 2011-08-22 |
| AU2009243184A1 (en) | 2009-11-05 |
| CN102037016A (zh) | 2011-04-27 |
| EP2280732A2 (en) | 2011-02-09 |
| JP5688363B2 (ja) | 2015-03-25 |
| KR101852915B1 (ko) | 2018-04-27 |
| NZ588850A (en) | 2012-12-21 |
| EP2280732A4 (en) | 2012-11-14 |
| KR20170126458A (ko) | 2017-11-17 |
| CA2722137A1 (en) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL208980A0 (en) | Antibodies to granulocyte-macrophage colony-stimulating factor | |
| SG10201701323TA (en) | Antibodies to ccr2 | |
| EP2125890A4 (en) | ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4 | |
| EP2461334B8 (en) | Inductor | |
| PT2150085T (pt) | Técnicas para melhorar a coexistência entre múltiplos rádios | |
| GB0815216D0 (en) | Interleukin | |
| IL215696A0 (en) | Antibodies specific to cadherin-17 | |
| EP2423182A4 (en) | DIACYLETHYLENEDIAMINE COMPOUND | |
| GB0903759D0 (en) | Compound | |
| PL2488554T3 (pl) | Przeciwciała przeciw epha3 | |
| GB0922659D0 (en) | Factor H | |
| GB0914767D0 (en) | Compound | |
| GB2468871B (en) | Turbocharger | |
| GB0909213D0 (en) | Compound | |
| GB0816577D0 (en) | Growth factor | |
| EP2424402A4 (en) | AVERAGE OF REGULATED CONTRIBUTION | |
| EP2487178A4 (en) | PYRAZOLOTHIAZOLVERBINDUNG | |
| EP2413751A4 (en) | IMPROVEMENTS RELATING TO COVERAGE | |
| GB0914883D0 (en) | Compound | |
| GB201013836D0 (en) | Improvements relating to gutters | |
| GB0806603D0 (en) | Improvements to emissions control | |
| GB0906429D0 (en) | Burn compound | |
| GB0801891D0 (en) | Brekkie to go range | |
| TWM365707U (en) | Improved structure for compound type outer pot | |
| GB0907825D0 (en) | Novel compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |